Product Description
ADX-914 is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP. (Sourced from: https://ir.horizontherapeutics.com/news-releases/news-release-details/q32-bio-and-horizon-therapeutics-plc-announce-dosing-first)
Mechanisms of Action: IL7 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: Fast Track - Alopecia Areata *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Q32 Bio
Company Location: Eastern America
Company Founding Year: 2017
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Poland, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Q32 Bio presented P2 Alopecia Areata results on 2026-07-13 for Bempikibart
- Clinical Outcomes Expected - Q32 Bio announced they will present P2 Alopecia Areata results in 3Q26 for Bempikibart
Highest Development Phases
Phase 2: Alopecia Areata|Dermatitis|Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06018428 |
SIGNAL-AA | P2 |
Active, not recruiting |
Dermatitis|Alopecia Areata |
2026-06-01 |
12% |
2025-11-01 |
Primary Endpoints |
NCT05509023 |
SIGNAL-AD | P2 |
Active, not recruiting |
Dermatitis, Atopic |
2024-12-01 |
2024-10-04 |
Primary Endpoints |
|
2023-510238-10-00 |
ADX-914-202 | P2 |
Completed |
Dermatitis, Atopic |
2024-12-10 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/08/2026 |
News Article |
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference |
|
12/01/2025 |
News Article |
Q32 Bio Sells Complement Inhibitor ADX-097 |
|
10/21/2025 |
News Article |
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata |
|
08/28/2025 |
News Article |
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference |